Gastroesophageal Reflux Disease (GERD) Market Summary

GERD Insights and Trends

• As per DelveInsight’s analysis, the United States accounted for the largest share of the 7MM market, reaching approximately USD 3,400 million in 2025.
• Chronic use of PPIs is associated with concerns around nutrient malabsorption, renal effects, and potential microbiome alterations, with many patients remaining on prolonged therapy without clear indications. This underscores a growing need for safer, more targeted treatment approaches.
• The GERD landscape demonstrates a pronounced age-related gradient, with disease burden peaking in the elderly population. In the United States, patients aged =60 years account for approximately 50% of total cases in 2025.
• Linaprazan glurate (X842) and Tegoprazan (BLI5100) represent key pipeline candidates expected to diversify the market by 2036. These next-generation P-CABs aim to offer improved durability and faster symptom relief, potentially replacing traditional H2RAs and PPIs in the refractory segment.
• The treatment paradigm remains heavily dominated by Proton Pump Inhibitors (PPIs); however, the landscape is gradually evolving with the emergence of Potassium-Competitive Acid Blockers (P-CABs), such as VOQUEZNA, which are gaining attention due to their faster onset of action and more consistent acid suppression.
• The emergence of novel oral formulations is expected to improve patient compliance and overall treatment outcomes. While Antacids and H2RAs maintain a presence for on-demand symptomatic relief, the therapeutic focus is clearly transitioning toward high-efficacy, long-acting acid-suppression technologies.

GERD Market size and forecast (The United States)

• 2025 Aggregate Market Size: USD 3,400 million
• Projected 2036 GERD Market Size: USD 5,700 million
• Market Growth Rate (2026–2036): 6% CAGR

DelveInsight’s ‘Gastroesophageal Reflux Disease – Market Insights, Epidemiology and Market Forecast - 2036’ report delivers an in-depth understanding of GERD, historical and forecasted epidemiology, as well as the market trends in the United States, EU4, the United Kingdom, and Japan.

The GERD market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, GERD patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2026 –2036) across global regions. The report highlights key unmet medical needs in GERD and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, and Spain and the UK
• Asia-Pacific: Japan

GERD Understanding and Treatment Algorithm

GERD Overview and Diagnosis

Gastroesophageal Reflux Disease (GERD) is a chronic, relapsing condition characterized by the reflux of gastric contents into the esophagus, leading to symptoms such as heartburn, regurgitation, chest discomfort, and potential mucosal injury. In the US, GERD remains one of the most prevalent Gastrointestinal (GI) disorders, significantly impacting quality of life and driving high utilization of primary care, gastroenterology consultations, OTC products, and prescription therapies.

Diagnosis remains challenging, as no single test defines GERD. Evaluation relies on symptom assessment, esophagogastroduodenoscopy (EGD), and pH-impedance monitoring for patients with atypical or refractory symptoms. Many patients self-medicate using OTC PPIs or antacids without diagnostic workup, delaying optimized therapy and obscuring true disease severity in real-world data.

Further details are provided in the report.

Current GERD Treatment Landscape

Medications used to treat GERD include antacids that neutralize gastric acid, as well as several classes of drugs that reduce gastric acid production: Histamine-2-receptor antagonists (H2RA), PPIs, and potassium-competitive acid blockers (P-CAB). Antacids are used on an as-needed basis to treat symptoms of dyspepsia or reflux, including heartburn. VOQUEZNA (vonoprazan), the first branded P-CAB in the US, represents a major therapeutic shift by delivering faster onset and superior 24-hour acid control compared to traditional therapies. This innovation addresses a critical gap in the current treatment landscape, which is heavily dominated by generic PPIs and H2RAs.

Further details related to country-based variations are provided in the report.

GERD Unmet Needs

The section “unmet needs of GERD” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

• Persistent Heartburn and Incomplete Symptom Control on PPIs.
• Reducing Disparities in Access to Advanced Testing and Procedures.
• Early Detection and Surveillance of Barrett's esophagus and Cancer Risk.
• Improving Treatment Adherence and Patient Engagement.

Note: Comprehensive unmet needs insights in GERD and their strategic implications are provided in the full report.

GERD Epidemiology

Key Findings from GERD Epidemiological Analysis and Forecast

• The GERD prevalent population represents a massive disease burden, with EU4 and the UK accounting for approximately 74 million cases in 2025.
• A consistent female predominance is observed across the regions; in the US, females account for 60% of cases in 2025, while in EU4 and the UK, they represent approximately 55% in 2025, indicating a modest but clear gender-based gradient in disease prevalence.
• Clinical segmentation reveals that Non-Erosive Reflux Disease (NERD) is the most common presentation, accounting for approximately 70% of all GERD cases. The remaining 30% are classified as Erosive Esophagitis in the US in 2025.                 

GERD Analysis & Competitive Landscape

The GERD drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the GERD treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the GERD therapeutics market.

Approved Therapies for GERD

Vonoprazan (VOQUEZNA): Phathom Pharmaceuticals/Takeda

Vonoprazan (VOQUEZNA), tablets contain vonoprazan, an oral small molecule, potassium-competitive acid blockers (P-CABs). PCABs are a novel class of medicines that block acid secretion in the stomach. VOQUEZNA is approved in the US for the treatment of adults with erosive esophagitis, also known as Erosive GERD, the relief of heartburn associated with erosive GERD, the relief of heartburn associated with nonerosive GERD, and for the treatment of H. pylori infection in combination with either amoxicillin or amoxicillin and clarithromycin.

In July 2024, Phathom Pharmaceuticals announced that the US FDA had approved VOQUEZNA (vonoprazan) 10 mg tablets for the relief of heartburn associated with nonerosive GERD in adults.

GERD Pipeline Analysis

Linaprazan Glurate : Cinclus Pharma

Linaprazan glurate (X842), a next-generation P-CAB being developed by Cinclus Pharma, is currently in Phase III development with topline results expected in H2 2026. Originally derived from AstraZeneca’s research, this prodrug offers superior pharmacokinetics and is anticipated to launch in 2027.

GERD Key Players, Market Leaders and Emerging Companies

• Braintree Laboratories
• Cinclus Pharma
• Phathom and others

GERD Drug Updates

• In November 2025, Cinclus Pharma has advanced into late-stage development with the launch of its first Phase III trial, and patient enrollment is progressing as planned. Topline data are anticipated in the second half of 2026 and could serve as a major value catalyst for the company.
• In August 2025, Braintree Laboratories, a subsidiary of Sebela Pharmaceuticals, reported positive topline results from the 24-week maintenance phase of the pivotal Phase III TRIUMpH study evaluating tegoprazan, a novel P-CAB, for the treatment of GERD.
• In July 2024, Phathom Pharmaceuticals announced that the US FDA had approved VOQUEZNA (vonoprazan) 10 mg tablets for the relief of heartburn associated with nonerosive GERD in adults.

GERD Market Outlook

Gastroesophageal Reflux Disease (GERD) is a chronic, relapsing gastrointestinal disorder characterized by the reflux of gastric contents into the esophagus, leading to symptoms such as heartburn, regurgitation, chest discomfort, and mucosal injury. Across the EU4 and the UK, GERD represents a substantial public health burden, significantly impairing quality of life and driving high utilization of primary care services, gastroenterology consultations, OTC medications, and long-term prescription therapies.

Key marketed therapies shaping current management

Vonoprazan (VOQUEZNA): Phathom Pharmaceuticals: It contain vonoprazan, an oral small molecule, potassium-competitive acid blockers (P-CABs). PCABs are a novel class of medicines that block acid secretion in the stomach. VOQUEZNA is approved in the US for the treatment of adults with erosive esophagitis, also known as Erosive GERD, the relief of heartburn associated with erosive GERD, the relief of heartburn associated with nonerosive GERD, and for the treatment of H. pylori infection in combination with either amoxicillin or amoxicillin and clarithromycin.

And more

Overall, the launch of first-in-class therapies, improved genetic testing, and rising disease awareness are expected to drive steady growth in the 7MM GERD market from 2022–2036, with strong commercial implications for both marketed products and emerging pipelines.

• The market size for GERD disease in the US was valued at approximately USD 3,400 million in 2025.
• VOQUEZNA (vonoprazan) has established its early presence as the first US P-CAB, projected to expand rapidly as demand rises for faster and more durable acid suppression beyond conventional PPIs.
• Leading companies like Braintree Laboratories and Cinclus Pharma are advancing the GERD pipeline with promising therapies such as BLI5100 (Tegoprazan) and Linaprazan glurate (X842). These clinical-stage candidates aim to address the significant unmet need within the PPI-refractory patient segment in the coming years

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in GERD (2022–2036 Forecast)

The treatment landscape of GERD is rapidly evolving, with a diverse pipeline spanning small molecules, collectively aiming to deliver more targeted, durable, and potentially disease-modifying outcomes beyond conventional immunosuppression.

Small Molecule Therapies- The GERD treatment landscape is evolving with the introduction of Potassium-Competitive Acid Blockers (P-CABs), a novel class of small molecules that offer faster and more sustained acid suppression compared to traditional PPIs. VOQUEZNA (vonoprazan) has already established its presence in the US for treating Erosive and Non-Erosive GERD, while next-generation candidates like BLI5100 (tegoprazan) and Linaprazan glurate (X842) are being developed by Braintree and Cinclus Pharma to provide superior efficacy and rapid onset.

GERD Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the GERD drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

BLI5100: It is an orally administered small-molecule inhibitor targeting the complement system to drive inflammation control. By selectively inhibiting Factor B, it addresses the alternative complement pathway. In the current market model, this therapy is projected to follow a slow-medium uptake.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in GERD

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The United States

VOQUEZNA (vonoprazan) provides cost-saving opportunities for eligible patients through its Savings Card Program, along with support resources to guide them throughout treatment. Under this program, commercially insured individuals who qualify may pay as little as USD 25 for a 30-day prescription.

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report….

GERD therapies Price Scenario & Trends

Pricing and analogue assessment of GERD therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Pricing of GERD Approved Drugs

To analyze the cost of VOQUEZNA, dosing schedules and treatment durations were first established based on approved recommendations. The unit price of VOQUEZNA was identified as USD 22.75. For erosive esophagitis, the recommended regimen consists of 20 mg once daily for 8 weeks, followed by 10 mg once daily for up to 6 months as maintenance. In NERD, the recommended dosing is 10 mg once daily for 4 weeks. Using these dosing patterns, treatment frequencies, and the unit cost, the final estimated annual cost of VOQUEZNA was calculated to be approximately USD 2,100.

Industry Experts and Physician Views for GERD

To keep up with GERD market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the GERD emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 8+ KOLs to gather insights at country level. Centers such as the Memorial Sloan Kettering Cancer Center, University of California San Francisco, State University of New York Upstate Medical University, etc. were contacted.

Their opinion helps understand and validate current and emerging GERD therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in GERD.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of GERD, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of GERD, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the GERD market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM GERD market.

Report Insights

• GERD Patient population forecast
• GERD therapeutics market size
• GERD pipeline analysis
• GERD market size and trends
• GERD market opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) bottom-up forecasting
• Artificial Intelligence (AI)-enabled market research report
• 11-year forecast
• GERD market outlook (North America, Europe, Asia-Pacific)
• GERD Burden trends (by geography)
• GERD Treatment addressable Market (TAM)
• GERD Competitive Landscape
• GERD major companies Insights
• GERD Price trends and analogue assessment
• GERD Therapies Drug Adoption/Uptake
• GERD Therapies Peak Patient Share analysis

Report Assessment

• GERD Current treatment practices
• GERD Unmet needs
• GERD Clinical development Analysis
• GERD emerging drugs product profiles
• GERD Market attractiveness
• GERD Qualitative analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the GERD market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of GERD?
• What are the disease risks, burdens, and unmet needs of GERD? What will be the growth opportunities across the 7MM concerning the patient population with GERD?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of GERD? What are the current guidelines for treating GERD in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the GERD market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.